



## Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025

December 19, 2024

SAN DIEGO--(BUSINESS WIRE)--Dec. 19, 2024-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Catherine Owen Adams, Chief Executive Officer will represent the Company in a session scheduled on Tuesday, January 14, 2025, at 9:00 a.m. Pacific Time / 12:00 p.m. Eastern Time.

A live webcast of Acadia's presentation will be accessible on the company's website, [Acadia.com](https://www.acadia.com), under the investors section and an archived recording will be available on the website for approximately one month following the presentation.

### *About Acadia Pharmaceuticals*

Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson's disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer's disease psychosis and multiple other programs targeting neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at [Acadia.com](https://www.acadia.com) and follow us on [LinkedIn](#) and [X](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20241219997230/en/): <https://www.businesswire.com/news/home/20241219997230/en/>

### *Investor Contact:*

Acadia Pharmaceuticals Inc.

Al Kildani

(858) 261-2872

[ir@acadia-pharm.com](mailto:ir@acadia-pharm.com)

Source: Acadia Pharmaceuticals